Glycopyrronium + BFF for Asthma

(FAROS Trial)

This trial explores the effectiveness of a new inhaler treatment for children with asthma. It tests two doses of glycopyrronium, a medicine that helps open airways, alongside an existing treatment, BFF, to assess improvements in lung function. Children aged 4 to 11, diagnosed with asthma by a doctor and currently using specific asthma medications, are suitable candidates for participation. The study uses different sequences of treatment to identify the best combination. As a Phase 2 trial, this research measures the treatment's effectiveness in an initial, smaller group of participants.

Yes, you will need to stop taking certain medications. The trial requires that you only use the run-in BFF MDI and albuterol/salbutamol as needed, and you cannot use long-acting muscarinic antagonists, systemic beta-blockers, systemic corticosteroids, or certain biologics.

Research has shown that glycopyrronium is generally safe for people with asthma. One study found that a glycopyrronium inhaler improved breathing without causing serious side effects. The most common issues were mild, such as needing a rescue inhaler like salbutamol, especially in the first few weeks. Another study found that glycopyrronium, when combined with another medication, was safe and effective for asthma patients. Overall, these studies suggest that glycopyrronium is safe and typically only causes minor side effects.¹²³⁴⁵

Researchers are excited about Glycopyrronium for asthma because it offers a novel approach by combining with BFF (Budesonide/Formoterol Fumarate), which could enhance bronchodilation and anti-inflammatory effects. Unlike standard treatments like inhaled corticosteroids or long-acting beta-agonists alone, Glycopyrronium acts as a long-acting muscarinic antagonist (LAMA), potentially providing more comprehensive airway relaxation. This combination may improve lung function and symptom control more effectively than current options. Additionally, it could offer a new line of defense for patients who don't fully respond to existing therapies.

Studies have shown that glycopyrronium, when combined with other medications, improves lung function in people with asthma. In one study, patients noticed improved breathing as quickly as five minutes after the first dose. Another study found that glycopyrronium reduced the frequency of moderate to severe asthma attacks. Research also shows that glycopyrronium eases breathing by significantly reducing airway sensitivity. Overall, these findings suggest glycopyrronium could be a promising treatment for asthma. Participants in this trial will receive glycopyrronium with other treatments in various sequences to further evaluate its effectiveness.²⁶⁷⁸⁹